ABSTRACT
Apolipoprotein L1 (APOL1) risk alleles in donor kidneys associate with graft loss but whether recipient risk allele expression impacts kidney transplant outcomes is unclear. To test whether recipient APOL1 allelic variants independently correlate with transplant outcomes, we analyzed genome-wide SNP genotyping data of donors and recipients from two kidney transplant cohorts, Genomics of Chronic Allograft Rejection (GOCAR) and Clinical Trials in Organ Transplantation 1/17 (CTOT1/17). We estimated genetic ancestry (quantified as proportion of African ancestry or pAFR) by ADMIXTURE and correlated APOL1 genotypes and pAFR with outcomes. In the GOCAR discovery set, we observed that the number of recipient APOL1 G1/G2 alleles (R-nAPOL1) associated with increased risk of death-censored allograft loss (DCAL), independent of genetic ancestry (HR = 2.14; P = 0.006), and within the subgroup of African American and Hispanic (AA/H) recipients (HR = 2.36; P = 0.003). R-nAPOL1 also associated with increased risk of any T cell-mediated rejection (TCMR) event. Analysis of the CTOT cohort validated these associations. Ex vivo studies of peripheral blood mononuclear cells revealed unanticipated high APOL1 expression in activated CD4+/CD8+ T cells and natural killer cells. We detected enriched immune response gene pathways in G1/G2 allele carriers vs. non-carriers among patients on the kidney waitlist and healthy controls. Together our findings highlight a previously unrecognized contribution of recipient APOL1 risk alleles to renal allograft outcomes. This immunomodulatory role has broader implications for immune mediated injury to native kidneys.
Competing Interest Statement
BM reports personal fees from ITBMed Biopharmaceuticals and stock in RenalytixAI. WZ reports personal fees from RenalytixAI. In addition, BM and WZ report the following patents: (i) US Provisional Patent Application F&R reference 27527-0134P01, serial number 61/951,651, filed March 2014: Method for identifying kidney allograft recipients at risk for chronic injury; (ii) US Provisional Patent Application: Methods for diagnosing risk of renal allograft fibrosis and rejection (miRNA); (iii) US Provisional Patent Application: Method for diagnosing subclinical acute rejection by RNA sequencing analysis of a predictive gene set; and (iv) US Provisional Patent Application: Pretransplant prediction of post-transplant acute rejection. RBC reports personal fees from Shire/Takeda, CSL Behring, Alexion, and eGenesis; in addition, RBC reports royalties from Entyvio (for inflammatory bowel disease). KH receives financial compensation from Sema4 (an Icahn School of Medicine at Mount Sinai spin-off company). Sema4 is currently majority owned by the Icahn School of Medicine at Mount Sinai.
Clinical Trial
GOCAR (Genomics of Chronic Renal Allograft Rejection): NCT00611702; CTOT01 (Noninvasive Monitoring to Predict Outcome in De Novo Kidney Transplant) Recipients): NCT00308802
Funding Statement
MCM and ZZ acknowledge the Translational Collaborative Research Initiative Grant, Non-HLA donor-recipient differences and allograft survival, Department of Medicine, and the computational resources and staff expertise provided by Scientific Computing at the Icahn School of Medicine at Mount Sinai. MCM acknowledges funding from American Heart Association (AHA 15SDG25870018), NIH DK122164, and pilot funding from the CTOT-19 study (PI: Peter Heeger; NIH U01AI063594) to study non-HLA donor-recipient genetic differences. The data reported here are substudies of the GOCAR study (PI: B. Murphy) supported by NIH U01AI070107-03 and the CTOT-01 study (PI: P. Heeger) supported by NIH U01AI63594-06. KH is partially supported by NIEHS 1R01ES029212-01, NIA AG058635, NIDDK U24DK062429 and DK106593.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
For the GOCAR (Genomics of Chronic Renal Allograft Rejection) study, study protocol and ethical approval was obtained from all the following respective ethics committees / Institutional Review Boards prior to study enrollment: Program for the Protection of Human Subjects / Institutional Review Board, Icahn school of Medicine at Mount Sinai, New York, New York, United States; Human Research Ethics Committee, University of Sydney, Westmead Hospital, Sydney, New South Wales, Australia; Health Sciences Institutional Review Board, University of Wisconsin at Madison, Madison, Wisconsin, United States; Office for Research, Institutional Review Board, Northwestern University, Chicago, Illinois, United States; Research Compliance office, The Human Research Committee, Massachusetts General Hospital-Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States. For the CTOT01/17 (Noninvasive Monitoring to Predict Outcome in De Novo Kidney Transplant) study, study protocol and ethical approval was obtained from all the following respective ethics committees / Institutional Review Boards prior to study enrollment: Program for the Protection of Human Subjects / Institutional Review Board, Icahn school of Medicine at Mount Sinai, New York, New York, United States; Institutional Review Board, University Hospitals of Cleveland, Cleveland Medical Center, Cleveland, Ohio, United States; Human Research Protection Program, Institutional Review Board, Yale University School of Medicine, New Haven, Connecticut, United States; Institutional Review Board, Cleveland Clinic Foundation, Cleveland, Ohio, United States; Office of Research Ethics, University of Manitoba, Winnipeg, Manitoba, Canada; Institutional Review Board and Research Administration Board, Emory University, Atlanta, Georgia, United States.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Conflict of Interest Statement BM reports personal fees from ITBMed Biopharmaceuticals and stock in RenalytixAI.WZ reports personal fees from RenalytixAI. In addition, BM and WZ report the following patents: (i) US Provisional Patent Application F&R reference 27527-0134P01, serial number 61/951,651, filed March 2014: Method for identifying kidney allograft recipients at risk for chronic injury; (ii) US Provisional Patent Application: Methods for diagnosing risk of renal allograft fibrosis and rejection (miRNA); (iii) US Provisional Patent Application: Method for diagnosing subclinical acute rejection by RNA sequencing analysis of a predictive gene set; and (iv) US Provisional Patent Application: Pretransplant prediction of post-transplant acute rejection. RBC reports personal fees from Shire/Takeda, CSL Behring, Alexion, and eGenesis; in addition, RBC reports royalties from Entyvio (for inflammatory bowel disease). KH receives financial compensation from Sema4 (an Icahn School of Medicine at Mount Sinai spin-off company). Sema4 is currently majority owned by the Icahn School of Medicine at Mount Sinai.
Data Availability
Gene expression data from a subgroup of GOCAR patients was obtained from the GEO database (accession ID: GSE112927). Single cell RNA sequencing data from PBMC samples collected from two ESRD patients was obtained from GEO database (accession ID: GSE162470). DICE data was obtained from dbGaP (study accession number : phs001703).
